Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier is effective in treating the bite of the brown recluse spider.

Abstract: Methods and compositions are provided for the prevention and treatment of infectious diseases such as syphilis, tuberculosis, pneumonia, other bacterial infections, AIDS, and other viral infections. Many of the compositions are active against carbon monoxide dehydrogenase (“CODH”), and include substances such as antigens, antibodies specific for CODH, and other inhibitors of CODH such as nickel and molybdenum metal chelators. The methods and compositions are particularly suited for treatment of diseases from previously under recognized anaerobic or facultative anaerobic pathogens such as Mycobacterium tuberculosis and Mycobacterium pneumonia.

Abstract: The invention is directed to a dietary supplement which contains mannoheptulose. Mannoheptulose occurs naturally in avocado fruit. The dietary supplement and its method of use can lower serum insulin levels and lower a subject's weight. The dietary supplement in its disclosed form includes a controlled release system for mannoheptulose. The dietary supplement may also include one or more amino acids.

Abstract: The present invention relates to me methods for minimizing spasticity in blood vessels during transplantation and more particularly for minimizing spasticity in arterial transplants, for both ex-vivo and in-vivo procedures. The invention also relates to formulations, which can be used in these methods.

Abstract: A solution and the method of making the same for the treatment of osteoarthritis for treating symptoms of osteoarthritic conditions. The solution and the method of making the same for the treatment of osteoarthritis includes magnesium oxide; ethylenediaminetetraacetic acid; glycerin; and water, all of which are heated and added in a mixture which, after being cooled, is applied to the affected areas for treatment of the osteoarthritic condition.

Abstract: The present invention is directed to the use of compounds of Formula (I), as active principals for treating skin conditions and compositions containing these compounds wherein R4 is (CR5R6-CR7R81-X1)n-CR9R10R11; n is an integer from 1 to 18; R1, R2, R3, R5, R6, R7, R8, R9, R10 and R11, are independently, herein defined and X, X1, Y and Z are independently, 0, NH or S.

Abstract: The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective to treat the glial tumor.

Abstract: The use of a novel mono-cationic salt of N,N′-bis(2-hydroxybenzyl) ethylenediamine-N,N′-diacetic acid (HBED) in iron chelating therapy is disclosed. In particular, the invention relates to the subcutaneous use of a mono cationic salt of HBED for treating a human with a disease treatable by an iron chelator such as iron overload, especially transfusional iron overload.

Abstract: A pharmaceutical composition comprising at least one antifungal agent and at least one chelator, and a method for administering the pharmaceutical composition to a patient having a fungal infection. Another aspect provides a pharmaceutical composition comprising at least one chelator, at least one antifungal agent and at least one monoclonal antibody, wherein the monoclonal antibody is operatively attached to the chelator, and a method of administering this composition to a patient having a fungal infection.

Abstract: A composition containing an EDTA complex is provided. More specifically, the EDTA complex is a magnesium di-potassium EDTA complex. The complex may be administered to a patient in several forms and may contain a controlled release agent which will release the EDTA complex over a period of several hours.

Abstract: This invention provides compounds of the formula: 1

Abstract: This invention provides processes for preparing a group of novel bridged tricyclic compounds having the formula: 1

Abstract: A composition containing a continuous aqueous phase comprising L-2-oxothiazolidine-4-carboxylic acid, at least one sequestering agent and at least one neutralizing agent, the said neutralizing agent being present in an amount which is sufficient to adjust the pH of the aqueous phase of the composition to a value of between 5 and 8. The combination of the sequestering agent and the neutralizing agent stabilizes the L-2-oxothiazolidine-4-carboxylic acid, in particular with respect to thermal degradation, and thus prevents yellowing of the composition and the formation of unpleasant odors.

Abstract: A hair and scalp formulation based on a peroxidase enzyme and synergistic yeast extract therefore. It entails a chemically-inert carrier material, a germicidal/preservative agent, and a metal chelating agent. A skin protective formulation based on peroxidase enzyme and yeast extract. It entails a polymer carrier, a fatty acid emollient, a co-emulsifier of an amino acid complex essential to a fatty acid; an emulsifying agent; a skin healing agent, and a germicidal surfactant. An aqueous formulation adapted for topical hair rinsing consisting of a peroxidase enzyme, a yeast extract adapted to enhance the activity of the enzyme and a cationic hair conditioning agent selected from water-soluble thickening resins.

Abstract: Pharmaceutical compositions containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics.

Abstract: The present invention relates to small molecules according to the formula [I]: which are potent inhibitors of &agr;4&bgr;1 mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing &agr;4&bgr;1 adhesion mediated conditions in a mammal such as a human.

Abstract: A composition containing an EDTA complex in the form of a suppository is provided. More specifically, the EDTA complex is a magnesium di-potassium EDTA complex. The suppository may contain a controlled release agent which will release the EDTA complex over a period of several hours.

Abstract: Methods for inhibiting and/or reversing tau filament formation or polymerization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or polymerization. An especially preferred pharmaceutical composition contains an inhibitor of the general formula I wherein R1 is an aliphatic radical having one to six carbon atoms and wherein R2 and R3 independently are a second aliphatic radical having one to six carbon atoms, a hydroxyl-substituted aliphatic radical having one to six carbon atoms, or a pheny radical or a pharmaceutically acceptable salt of the inhibitor.

Abstract: A solid pharmaceutical composition for the oral administration of chelating agents to an individual consists essentially of: at least 100 milligrams of ethylenediamninctetraacetic acid (EDTA) or a molar equivalent amount of pharmaceutically acceptable salts or hydrated salts of EDTA, at least 75 milligrams of N-acetyl-L-cysteine, at least 10 milligrams of lactoferrin, and an appropriate amount of at least one pharmaceutical formulating agent.

Abstract: An enteral nutritional product for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

Abstract: Pharmaceutically active compounds are prepared as described and used to produce pharmaceutical preparations for treating diseases.

Abstract: A nutritional tablet or caplet has a film coating that contains folic acid available for rapid release upon contact with gastric fluid. The film coating also includes a film forming polymer such as hydroxypropyl methylcellulose.

Abstract: Novel compositions cobalamin and related corrinoids, and uses thereof, are disclosed. The novel compositions include a corrin, a first amino acid having a side chain which includes a basic or positively charged moiety; and a second amino acid with an uncharged side chain which includes at least one heteroatom. The compositions are useful for, inter alia, treatment of cobalamin deficiency.

Abstract: Disclosed are prodrug compounds of a class of alkyl carboxy amino acid analogs of glutamic acid that act as specific regulators of the kainate EAA receptor cation channel. These compounds are useful for treating neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders associated with excessive or insufficient activation of the kainate subtype of the ionotropic EAA receptors; treating cognitive disorders associated with deactivation, suboptimal activation or over-activation of the kainate receptor; alleviating pain and improving and enhancing memory, learning, and associated mental processes.

Abstract: A method for increasing the target-specific toxicity of a drug is effected by pretargeting an enzyme to a mammalian target site, and then administering a cytotoxic drug known to act at the target site, or a prodrug form thereof which is converted to the drug in situ, which drug is also detoxified to form an intermediate of lower toxicity using said mammal's ordinary metabolic processes, whereby the detoxified intermediate is reconverted to its more toxic form by the pretargeted enzyme and thus has enhanced cytotoxicity at the target site. Further enhancement can be achieved by pretargeting an enzyme which converts the prodrug to the cytotoxic drug at the target site. Kits for use with the method also are provided. The method and kits permit lower doses of cytotoxic agents, maximize target site activity and minimize systemic side effects.

Abstract: An antibacterial agent is provided, which has an action for inhibiting growth of Helicobacter pylori participating to occurrence of chronic gastritis and gastric ulcer, and a highly safe substance is used as an effective component therein. An antibacterial agent for Helicobacter pylori is characterized in that at least one substance selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts is contained as an effective component.

Abstract: This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).

Abstract: The invention relates to zinc-containing antiviral compositions and methods of treating viral infections. More specifically, the invention provides compositions and methods useful for ameliorating the symptoms of individuals suffering from infection with a broad range of viruses. Examples of viruses against which the compounds of the invention are active include rhinoviruses, varicella zoster, immunodeficiency viruses, including HIV.

Abstract: What is shown is an animal blood anticoagulant compound useful in the meat packing industry generally, and in slaughterhouse operations, particularly. The anticoagulant is effective when diluted with water at higher dilution ratios than earlier anticoagulants. In some field trials, this anticoagulant was at least as effective as previously known commercial anticoagulants when diluted by an additional 30%. The present anticoagulant preparation concentrate is an aqueous mixture of soft water (55.0%-65.0/%, w/w); tetrasodium ethylene diamine tetraacetate (Na4EDTA) (0.5%-3.0%, w/w); sodium hexametaphosphate (17.0%-24.0%, w/w); citric acid (5.0%-9.0%, w/w); and sodium hydroxide (4.0%-7.0%, w/w) to obtain a balanced pH that provides optimal chelating and anticoagulant activity. Optimal anticoagulant performance has been found to occur in the range of between pH 6.6 and pH 7.2.

Abstract: Method of oral administration of nutrients, nutraceuticals, and drugs to humans and animals orally by encapsulating these substances into vesicles formed by polar molecules, like phospholipids, for enhanced transport through oral mucosa or intestinal membranes into the circulatory system.

Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions and compositions for treatment of conditions caused by amyloidosis, A&bgr;-mediated formation of ROS, or both, such as Alzheimer's disease, are disclosed.

Abstract: The invention provides a method of treating a chronic ulcer, such as a diabetic ulcer, comprising administering a therapeutic amount of a hydrogel matrix to the ulcer, the matrix composition comprising gelatin and a long chain carbohydrate. The matrix may further include polar amino acids, nitric oxide inhibitors and super oxide inhibitors. Injection is a preferred method of administration. The matrix may be injected into one or more locations within the ulcer, underneath the ulcer and/or around the periphery of the ulcer.

Abstract: The invention provides compositions for topical use, comprising at least one glycoglyceride and at least one sequestering agent. The glycoglyceride has very good stability in the composition of the invention. The glycoglyceride is preferably a galactolipid such as digalactosyl diglyceride or monogalactosyl diglyceride. The sequestering agent may be chosen in particular from phosphonic derivatives and salts thereof. This composition may in particular constitute a cosmetic and/or dermatological composition.

Abstract: An ingestible mollusc poison contains a simple metal compound, an activity enhancing additive such as ethylene diamine disuccinic acid (EDDS) and derivatives thereof, and a carrier material edible to molluscs. In one embodiment the active agent of the mollusc poison may be in the form of a metal complex of EDDS. The composition may be used alone or in conjunction with molluscicidal co-active agents and/or fertilizers.

Abstract: An amino acid and/or a peptide are orally administrated to a neonatal ruminant whose fermenting function of the rumen has not yet developed thereby effecting a significant increase in the accumulation of fat between the muscle fibers as well as increase of the fattening effect during the fattening period.

Abstract: Compositions including glutamic acid and either glycolic acid or polyglycolic acid, salts of these compounds or combinations thereof are described as are such compositions that include a calcium salt, preferably calcium nitrate. Methods of treating a plant including treating the plant or seed with a composition including glutamic acid and either glycolic acid or polyglycolic acid, salts of the aforementioned compounds or combinations thereof, and optionally a calcium salt, are also described. The methods and compositions of the present invention are advantageous in increasing plant productivity, including helping plants resist the effects of a wide variety of plant stresses. Methods of stimulating microbial growth with the compositions of the present invention are also provided.

Abstract: The use of a mono-cationic salt of N,N′-bis(2-hydroxybenzyl)-ethylenediamine-N,N′-diacetic acid (HBED) in iron chelating therapy is disclosed. In particular, the invention relates to the intravenous use of a mono-cationic salt of HBED for treating a primate with a condition treatable by an iron chelator such as iron overload, especially transfusional iron overload.

Abstract: A hair and scalp formulation based on a peroxidase enzyme and synergistic yeast extract therefore. It entails a chemically-inert carrier material, a germicidal/preservative agent, and a metal chelating agent. A skin protective formulation based on peroxidase enzyme and yeast extract. It entails a polymer carrier, a fatty acid emollient, a co-emulsifier of an amino acid complex essential to a fatty acid; an emulsifying agent; a skin healing agent, and a germicidal surfactant. An aqueous formulation adapted for topical hair rinsing consisting of a peroxidase enzyme, a yeast extract adapted to enhance the activity of the enzyme and a cationic hair conditioning agent selected from water-soluble thickening resins.

Abstract: Derivatives of o-nitromandelyoxycarbonyl (Nmoc) which are capable of releasing an amino acid (or derivative thereof), upon irradiation with ultraviolet (UV) light are disclosed, as well as a method for producing a free amino acid (or derivative thereof) employing the same, e.g., to study neurophysiology.

Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

Abstract: There is provided use of an amino acid derivative in free acid or salt form, in which the nitrogen atoms of two or more amino acid molecules are linked by a hydrocarbyl or substituted hydrocarbyl group, as an anti-fungal compound.

Abstract: This invention relates to a palatable elemental nutritional formula that is nutritionally complete for humans with specialized dietary needs. The nutritional of the present invention uses specific free amino acids to provide the source of amino nitrogen (protein equivalents) and a special blend of fats that provides 38 to 50% of the total Calories in a pleasant tasting formula. The nutritionally complete formula of this invention is useful for children having multiple protein allergies, short gut syndrome, sick gut, diarrhea and the like. More specifically, the nutritional product, in accordance with this invention, utilizes L-asparagine monohydrochloride and L-glutamine in place of L-aspartic acid and L-glutamic acid, respectively. In addition, the source of fat comprises soy, fractionated coconut oil (medium chain triglycerides), high oleic safflower oil and esterified glycerol emulsifiers.

Abstract: The use of a novel mono-cationic salt of N,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) in iron chelating therapy is disclosed. In particular, the invention relates to the subcutaneous use of a mono cationic salt of HBED for treating a human with a disease treatable by an iron chelator such as iron overload, especially transfusional iron overload.

Abstract: The invention relates to an aqueous pesticide composition for killing dust mites, which contains a chelating agent as the active ingredient and a surfactant to facilitate distribution over, or subsequent removal from, the surfaces of fabric or fibrous materials, such as floor coverings, wall and window coverings, furniture coverings, etc. The invention also relates to methods of using the aqueous pesticide composition for killing dust mites and controlling the dust mite population in the indoor living environment and for cleaning carpets and rugs.

Abstract: Anionic surfactants are used in conjunction with an antifungal acid and a chelating agent to preserve topically administrable pharmaceutical compositions without the need for a conventional preservative such as benzalkonium chloride.

Abstract: Use of (S,S)-N,N'-ethylenediamine disuccinate (EDDS) of formula I wherein M.dbd.H.sup.+ and/or any pharmaceutically acceptable cation, for the preparation of a medicament for the treatment of cytomegaloviral infections which has immunosuppressive properties.

Abstract: The present invention is directed to a sterile pharmaceutical composition comprising a propofol containing oil-in-water emulsion formulation having as an antimicrobial agent, a member selected from the group consisting of benzyl alcohol and sodium ethylene diamine tetraacetate; benzethonium chloride; and benzyl alcohol and sodium benzoate.

Abstract: The present invention relates to compounds of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and psychiatric disorders.

Abstract: A solid pharmaceutical composition for the oral administration of chelating agents to an individual consists essentially of: at least 100 milligrams of ethylenediaminetetraacetic acid (EDTA) or a molar equivalent amount of pharmaceutically acceptable salts or hydrated salts of EDTA, at least 75 milligrams of N-acetyl-L-cysteine, and an appropriate amount of at least one pharmaceutical formulating agent.

Abstract: The present invention relates to the compound of formulae ##STR1## and to a process for the manufacture of compounds of the general formula ##STR2## which are ligands for the metabotropic glutamate receptors of group II, whereinT is tritium;R.sup.1 is hydroxy, lower alkoxy, lower alkenyloxy, benzyloxy, hydrogen, deuterium or tritium;R.sup.11 is hydrogen, deuterium or tritium, hydroxy or amino, andR.sup.2 is hydrogen or tritium, orR.sup.1 and R.sup.2 form a bond.